VASCULAR MALFORMATIONS
Clinical trials for VASCULAR MALFORMATIONS explained in plain language.
Never miss a new study
Get alerted when new VASCULAR MALFORMATIONS trials appear
Sign up with your email to follow new studies for VASCULAR MALFORMATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Matched conditions: VASCULAR MALFORMATIONS
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Electric shock therapy may shrink blood vessel birthmarks
Disease control Recruiting nowThis study is testing a treatment called electrosclerotherapy for people with low-flow venous malformations (abnormal blood vessels present from birth). The goal is to shrink the malformation by at least 30% and reduce pain. About 65 participants will receive the treatment and be…
Matched conditions: VASCULAR MALFORMATIONS
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare vascular malformations: targeted drugs enter trial
Disease control Recruiting nowThis phase 2 trial is testing two targeted drugs—alpelisib and mirdametinib—in 50 people with slow-flow or fast-flow vascular malformations that haven't responded to standard treatments. The goal is to see if these drugs can improve each person's most bothersome symptom over 48 w…
Matched conditions: VASCULAR MALFORMATIONS
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a cancer drug tame tangled blood vessels?
Disease control Recruiting nowThis Phase 2 trial tests the oral drug everolimus in 10 adults with vascular malformations—abnormal clusters of blood vessels. The goal is to see if the drug can shrink these lesions and reduce complications like bleeding. Participants take everolimus daily for up to a year, with…
Matched conditions: VASCULAR MALFORMATIONS
Phase: PHASE2 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC